COBOLIMAB
UNII 3K5H4TX2KP

Substance Identification & Data

This profile provides standardized clinical and technical data for Cobolimab, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 3K5H4TX2KP.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2022215-65-0 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

3K5H4TX2KP

CAS Registry Number

2022215-65-0

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

COBOLIMAB

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C128627

National Cancer Institute reference terminology for clinical and research data.

INN ID

10788

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

EF-56

Identifier assigned by the United States Adopted Names Council.

Substance Type

protein

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Cobolimab. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

COBOLIMAB

Common Names & Synonyms

COBOLIMAB [INN]

COBOLIMAB [USAN]

COBOLIMAB [WHO-DD]

Systematic Nomenclature

IMMUNOGLOBULIN G4, ANTI-(HEPATITIS A VIRUS CELLULAR RECEPTOR 2 (HAVCR2)) (HUMANIZED CLONE ABT2 .GAMMA.4-CHAIN), DISULFIDE WITH HUMANIZED CLONE ABT2 .KAPPA.-CHAIN, DIMER

SYS

IMMUNOGLOBULIN G4-KAPPA, ANTI-(HOMO SAPIENS HAVCR2 (HEPATITIS A VIRUS CELLULAR RECEPTOR 2, T-CELL IMMUNOGLOBULIN MUCIN FAMILY MEMBER 3, TIM-3, TIM3, TIMD3, CD366)), HUMANIZED MONOCLONAL ANTIBODYGAMMA4 HEAVY CHAIN HUMANIZED (1-440) (VH (HOMO SAPIENS IGHV3-23*01 25^26>INS^A (25) (92.8%)-(IGHD)-IGHJ6*01 (92.9%)) (8.8.5) (1-113)-HOMO SAPIENS IGHG4*01 (CH1 (114-211), HINGE S10>P (221) (212-223), CH2 (224-333), CH3 (334-438), CHS (439-440)) (114-440)), (127-214')-DISULFIDE WITH KAPPA LIGHT CHAIN HUMANIZED (1'-214') (V-KAPPA (HOMO SAPIENS IGKV1-39*01 (90.5%)-IGKJ4*01 (100%)) (6.3.9) (1'-107')-HOMO SAPIENS IGKC*01 (100%), KM3 A45.1 (153), V101 (191) (108'-214'))DIMER (219-219'':222-222'')-BISDISULFIDE

SYS

IMMUNOGLOBULIN G4-KAPPA, ANTI-(HUMAN HEPATITIS A VIRUS CELLULAR RECEPTOR 2 (HAVCR-2, T-CELL IMMUNOGLOBULIN AND MUCIN DOMAIN-CONTAINING PROTEIN 3, T-CELL MEMBRANE RECEPTOR-3))HUMANIZED MONOCLONAL ANTIBODY: .GAMMA.4 HEAVY CHAIN (1-440) (HUMANIZED VH (HOMO SAPIENS IGHV3-23*01 (92%) (IGHD)-IGHJ6*01 (93%)) (8.8.6) (1-113)-HOMO SAPIENS IGHG4*01 (H S10>P(221)) (114-440)) (127-213')-DISULFIDE WITH KAPPA LIGHT CHAIN (1'-213') (HUMANIZED V-KAPPA (HOMO SAPIENS IGKV1-39*01 (91%) IGKJ4*01) (6.3.9) (1'-106')-HOMO SAPIENS IGKC*01 (107'-213')), DIMER (219-219'':222-222'')-BISDISULFIDE

SYS